Search
Rhein
go.drugbank.com/drugs/DB13174ExperimentalRhein is an anthraquinone metabolite of rheinanthrone and senna glycoside is present in many medicinal plants including Rheum palmatum, Cassia tora, Polygonum multiflorum, and Aloe barbadensis . It is known to have hepatoprotective, neph...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsAGS-004
go.drugbank.com/drugs/DB05742InvestigationalNon-personalized HIV immunotherapies are unable to raise cytotoxic T lymphocytes against HIV antigens, fail to induce T cell memory, and, most importantly, do not provide antiviral protection against the
Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media
go.drugbank.com/drugs/DB15728ExperimentalUmbilical-cord derived MSCs are currently being tested for numerous clinical applications due to their immunosuppressive and anti-inflammatory properties.
Arbaclofen Placarbil
go.drugbank.com/drugs/DB08892InvestigationalArbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned
Resveratrol
go.drugbank.com/drugs/DB02709InvestigationalIn a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersBevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigational[A286054] This off-label practice was formalized with the approval of Lytenava (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically
Viltolarsen
go.drugbank.com/drugs/DB15005ApprovedInvestigationalAlthough corticosteroids are effective in slowing disease progression in both DMD and BMD patients, they do not address the underlying molecular pathogenesis.
Seletracetam
go.drugbank.com/drugs/DB05885InvestigationalAs of 2010, its production was further halted due to the investigation of a newer antiepileptic agent, brivaracetam.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesVipadenant
go.drugbank.com/drugs/DB06625InvestigationalCategories: Purinergic P1 Receptor Antagonists